Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a directed share issue whereby the company raised proceeds of SEK 210 million before issue costs.
The Alfa eCare group is a recognized and rapidly growing software provider within the e-health sector that offers solutions to both private and public healthcare providers in the Nordics.
The Alfa eCare group is a recognized and rapidly growing software provider within the e-health sector that offers solutions to both private and public healthcare providers in the Nordics.
Vinge has advised the Danish VC fund People Ventures in conjunction with its investment in Leia Health, which has developed an app designed to map physical and mental health for postpartum women.
Velvet Cichlid has announced a public offer to the shareholders of Sleep Cycle AB (publ). The offer values the shares of Sleep Cycle at approximately SEK 862 million.
Vinge has advised Hansa Biopharma in connection with a directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs.
Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore Pharma receives gross proceeds of SEK 200 million.
Vinge has advised BICO Group AB in connection with a directed share issue to Sartorius AG, adding a total amount of MSEK 487 to BICO. The subscription price of SEK 76 was equivalent to a premium of 2.7 per cent compared with a 3-day VWAP. In connection with the share issue, BICO and Sartorius have entered into an extensive co-operation agreement concerning technical, sales and marketing issues.
The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.
Vinge has advised Xspray Pharma, a pharmaceutical company with several product candidates in clinical development listed on Nasdaq Stockholm, in connection with a share issue whereby the company raises proceeds of SEK 100 million.
Vinge has advised Nordea Bank Abp, filial i Sverige, Corporate Finance in connection with the rendering of a fairness opinion regarding Karo Intressenter’s public offer to the shareholders of Karo Pharma AB.
